|
||
© The Rockefeller University Press,
0021-9525/1999//1561 $5.00
The Journal of Cell Biology, Volume 147, Number 7,
, 1999 1561-1568
Original Article |
Bifurcation of Cell Migratory and Proliferative Signaling by the Adaptor Protein Shc
cheresh{at}scripps.edu
Cytokines and extracellular matrix proteins initiate signaling cascades that regulate cell migration and proliferation. Evidence is provided that the adaptor protein Shc can differentially regulate these processes. Specifically, under growth factor–limiting conditions, Shc stimulates haptotactic cell migration without affecting anchorage-dependent proliferation. However, when growth factors are present, Shc no longer influences cell migration; rather, Shc is crucial for DNA synthesis. Mutational analysis of Shc demonstrates that, while tyrosine phosphorylation is required for both DNA synthesis and cell migration, the switch in Shc signaling is associated with differential use of Shc's phosphotyrosine interacting domains; the PTB domain regulates haptotaxis, while the SH2 domain is selectively required for proliferation.
Key Words: Shc cell migration mitogenesis SH2 PTB
© 1999 The Rockefeller University Press
CELL migration and proliferation are essential to angiogenesis, embryonic development and wound healing. It has become clear that cell migration and proliferation depend on intracellular signals propagated by growth factors and adhesion proteins within the extracellular matrix (ECM). However, cell migration and DNA synthesis do not necessarily occur simultaneously. For example, neural crest cells migrate over long distances in the embryo yet fail to proliferate (Perris 1997). During wound repair, keratinocytes migrate into the wound before entry into the cell cycle (Martin 1997). Recent studies have determined that cell migration and proliferation utilize many of the same intracellular signaling pathways such as activation of Rho family proteins and the extracellular signal-related matrix (ERK) cascade (Pages et al. 1993; Olson et al. 1995; Anand-Apte et al. 1997; Klemke et al. 1997). However, signaling molecules likely exist that allow cells to differentially regulate cell migration and proliferation. Evidence is provided in this report that the adaptor protein Shc serves such a purpose.
The Shc family of adaptor proteins consists of multiple protein-protein interaction domains: an amino-terminal phosphotyrosine binding (PTB) domain a central collagen homology (CH) domain and a carboxy-terminal Src homology 2 (SH2) domain (Pelicci et al. 1992; Blaikie et al. 1994). Shc exists in three isoforms of 46, 52, and 66 kD, and was found to associate with and became tyrosine phosphorylated by the EGF receptor and to be capable of inducing anchorage-independent growth (Pelicci et al. 1992). After growth factor stimulation, p52 Shc is recruited to activated tyrosine kinase receptors through either its PTB or its SH2 domain, which leads to phosphorylation at tyrosine residues 239, 240, and 317 within the CH domain (Rozakis-Adcock et al. 1992; Gotoh et al. 1996; van der Geer et al. 1996). Tyrosine-phosphorylated Shc thus is able to recruit Grb2/SOS through a binding event between the Grb2 SH2 domain and Shc phosphotyrosine residues (Pelicci et al. 1992; Rozakis-Adcock et al. 1992), ultimately resulting in activation of Ras, the ERK cascade, and mitogenesis (Bonfini et al. 1996). Recent reports demonstrate that Shc also potentiates integrin signaling. For example, integrin ligation results in activation of tyrosine kinases such as Src, Fyn, and focal adhesion kinase (FAK) that phosphorylate Shc leading to Ras activation and entry into the cell cycle (McGlade et al. 1992; Mainiero et al. 1995; Wary et al. 1996, Wary et al. 1998; Schlaepfer et al. 1998).
In addition to their role in regulating DNA synthesis, growth factor receptors and integrins play a crucial role in cell migration and invasion (Klemke et al. 1994; Huttenlocher et al. 1995). This process involves rearrangement of the actin cytoskeleton, the formation of new integrin substratum contacts, cell contraction, and release of preexisting cell–matrix contacts at the trailing edge (Lauffenburger and Horwitz 1996). Previous reports have suggested a role for Shc in this process (Pelicci et al. 1995; Nolan et al. 1997). Therefore, experiments were designed to evaluate the role of Shc in cell migration and DNA synthesis. In this report, evidence is presented that Shc plays a critical role in regulating these cell biological events. Shc is required for cell migration, but not proliferation, when growth factors are limiting. However, in the presence of growth factors Shc no longer influences cell migration, but rather, is essential for DNA synthesis. A mutational analysis of Shc has helped to elucidate how a given adaptor protein can differentially activate cell migration and proliferation.
| Materials and Methods |
|---|
|
|
|---|
Cell Culture
FG-M cells were maintained in RPMI supplemented with 10% FBS, 1 µg/ml gentamicin, and 0.4 mM glutamine (gentamycin/glutamine; Sigma). Cells were used from passage 8 to passage 13. Cos-7 cells were maintained in DME supplemented with 10% FBS, 0.4 mM glutamine, and 1 µg/ml gentamicin. Cells were used from passage 6 to passage 20 and were mycoplasma free during the course of these studies.
Transfection
Cells were transfected with lac z (to identify transfected cells) and the indicated constructs on 10-cm tissue culture plates using LipofectAMINE (GIBCO BRL) per the manufacturer's instructions. Cos-7 cells were incubated in the transfection mixture for 5 to 7 h and FG-M cells were allowed to incubate for 15 h. At the end of this time, cells were returned to full growth medium for either 15 h (Cos-7 cells) or 8 h (FG-M) cells, and serum deprived for 20–24 h before use in experiments.
Generation of p52 Shc Stable Cell Line
Cos-7 cells were transfected with wild-type, murine p52 Shc cDNA subcloned into pCDNA3.1HisC using LipofectAMINE per the manufacturer's instructions. 3 d later, cells were passaged into growth medium supplemented with 500 µg/ml G418 to select for p52 Shc-expressing cells. After selection, cells were seeded at low density into 96-well plates, single colonies were isolated with a cloning ring, and expanded for two passages before experimental use.
Immunofluorescence
Acid-washed coverslips were coated with collagen (10 µg/ml) and nonspecific binding was blocked with 0.5% RIA grade BSA (Sigma). Serum-deprived cells were harvested as described below and seeded onto collagen-coated coverslips. Cells were allowed to spread for 2 h, then were fixed in 3.7% formaldehyde in PBS, permeabilized for 1 min in 0.01% Triton X-100, and actin was visualized by incubating the coverslips for 1 h with 2 µg/ml rhodamine conjugated phalloidin (Sigma). Coverslips were washed three times in PBS and three times in deionized water then mounted with gelvatol. Images were acquired with Bio-Rad MRC1024 confocal system using Bio-Rad Lasersharp software and a 63x objective on a Zeiss Axiovert 100. Images were processed with Adobe Photoshop.
Migration Assays
Motility experiments were performed as previously described (Klemke et al. 1998). In brief, Boyden chambers (Millipore Millicells, 8-mm pore size) were coated on either their lower surfaces with 10 µg/ml of the indicated extracellular matrix proteins for 2 h at 37°C. Chambers were then placed in 24-well culture dishes containing either serum-free DME supplemented with gentamicin, glutamine, and 0.5% BSA (RIA grade, "migration buffer"; Sigma) or migration buffer supplemented with 100 ng/ml EGF (mouse receptor grade; UBI) or 25 mg/ml insulin (human recombinant insulin; Boehringer Mannheim Biochemica) as indicated. Cells were harvested in buffer consisting of Hanks' balanced salt solution, 25 mM Hepes, 5 mM EDTA, and 0.01% trypsin. Next, cells were washed twice in serum-free DME containing 0.5% BSA and 150,000 cells were loaded into the upper portion of the Boyden chambers. Migrations were allowed to proceed for 4–6 h. At the end of this time, nonmigratory cells were removed with a cotton swab, and chambers were stained for β-galactosidase activity (to identify transfected cells) or stained with crystal violet. Migration was quantitated by blind counting the number of migratory cells on the lower surface of the membrane of at least two fields per chamber using a 20x objective. Statistical analysis was performed using InStat (Graph Pad) by pooling the data from multiple independent experiments.
Modified Migration Assays
Integrin antibody blocking experiments were performed as described above except that Cos-7 cells were mixed with the indicated anti-integrin antibodies immediately before loading into Boyden chambers; experiments were then allowed to proceed as above for 4 h. Random migration experiments were performed using chambers that had been coated with extracellular matrix protein on either their lower surfaces (haptotaxis) or their upper and lower surfaces (random migration). Video time-lapse microscopy was also attempted to assess random migration in serum-deprived cells on extracellular matrix protein; however, during the course of the experiment (6 h), Cos-7 cells did not migrate using this method.
Replating Assays, Immunoprecipitation, and Western Blotting
Petri dishes were coated with extracellular matrix proteins as indicated. Nonspecific binding of cells to plates were blocked by incubating with heat-denatured BSA for 30 min. Next, serum-deprived cells were harvested as described above and either left in suspension for 20 min or plated onto matrix-coated, blocked plates for the indicated times and harvested in a lysis buffer containing 10 mM Tris, pH 7.6, 150 mM sodium chloride, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, and 5 mM EDTA. The following inhibitors were added immediately before use: complete protease inhibitor (1 tablet/20 ml; Boehringer Mannheim), 1 mM PMSF, 2.5 mM sodium orthovanadate. Shc was either immunoprecipitated using a polyclonal Shc antibody (Transduction Labs) or His-tagged Shc was isolated using nickel agarose beads (Ni-NTA agarose; Qiagen). Phosphotyrosine was detected using the monoclonal anti-phosphotyrosine antibody, 4G10. Shc was detected using a either a monoclonal or a polyclonal Shc antibody. Bands were visualized by chemiluminescence (Super Signal; Pierce). Expression levels of Shc mutants in migration assays was determined by reserving an aliquot of cell lysate from the migration assay and analyzing it by Western blot with a polyclonal Shc antibody.
DNA Synthesis Assay
Cells were transfected as described above on coverslips. 24 h later, cells were serum starved overnight and stimulated with either serum-free DME or DME containing 100 ng/ml EGF. 12 h later, cells were incubated for an additional 6 h with bromodeoxyuridine (BrdU) to identify newly synthesized DNA. Coverslips were then washed with PBS and fixed in 3.7% formaldehyde. BrdU was quantitated in transfected cells by staining with a rat anti-BrdU antibody (Amersham) and a mouse antiExpress antibody (Invitrogen, to identify proteins expressed from pCDNA3.1HisC).
| Results |
|---|
|
|
|---|
|
2β1 to migrate on collagen (Klemke et al. 1997) suggesting that Shc's ability to transmit integrin-mediated signals for migration may be more permissive than previously observed for cell cycle progression (Wary et al. 1996). In agreement with the motility results, ligation of integrins with either collagen or vitronectin resulted in tyrosine phosphorylation of wild-type p52 Shc indicating that both of these ECM proteins support Shc phosphorylation (Fig. 2).
|
2β1 and
1β1 in this response, we first established concentrations of
1 (mAb 1973Z) and
2β1 (6F1) monoclonal antibodies that inhibited adhesion of Cos-7 cells to collagen (5 µg/ml of anti-
1 and 10 µg/ml of anti-
2β1, data not shown). Next, these concentrations of monoclonal antibodies were added to the cells immediately before placement in Boyden chambers. Both anti-
1 antibodies and
2β1 antibodies inhibited Shc's ability to promote cell migration;
2β1 antibodies had a more pronounced effect (Fig. 3). These data establish that
2β1 and Shc can signal along a common pathway resulting in cell movement. P4C10, an antibody directed against the shared β1 subunit, completely inhibited haptotaxis of mock and Shc transfected cells on collagen (data not shown). LM609, a function blocking monoclonal antibody to
vβ3, prevented Shc-stimulated migration towards vitronectin, but not on collagen (data not shown), further confirming that Shc requires integrins to effect cell movement.
|
Structural Requirements for Shc-induced Cell Motility
Having established a role for Shc in haptotaxis, mutational analysis was performed to identify regions of Shc that mediate this response. Several point mutants were employed for these studies (Fig. 4). To address the role of Shc tyrosine phosphorylation in cell migration, increasing amounts of cDNA encoding mutant forms of Shc bearing tyrosine to phenylalanine point mutations at residues 239/240 (Shc Y239F/Y240F), residue 317 (Shc Y317F) or both residues 239/240 and residue 317 (ShcY239F/Y240F/Y317F, Shc 3YF) were expressed in Cos-7 cells. With the exception of Shc 3YF, these mutants were expressed to similar extents as shown in Fig. 5 A. Next, cells expressing these mutants were allowed to migrate on a collagen or vitronectin substrate. Only wt Shc was found to significantly enhance cell migration (P < 0.01 by analysis of variance [ANOVA] of six independent experiments). Neither Y239/240F nor Y317F mutants stimulated motility substantially; although stimulation was observed by both of these mutants in certain experiments, it was not found to be statistically significant when all experiments were analyzed (P > 0.1 by ANOVA). The triple mutant, Shc 3YF, was unable to induce cell motility on either matrix (Fig. 5 a) and appeared to suppress migration somewhat. Therefore, tyrosine phosphorylation of both residues 239/240 and 317 appear to play a critical role in this response.
|
|
Shc Is Required for Haptotaxis of a Metastatic Tumor Cell
To establish whether Shc might be required for cell migration in general, experiments were performed using the constitutively migratory pancreatic carcinoma cell, FG-M. These cells, selected for their migratory properties in vitro, acquired a metastatic phenotype in vivo (Klemke et al. 1998). Shc was constitutively tyrosine phosphorylated in serum-deprived FG-M cells, even when cells are held in suspension (Fig. 6). This is in contrast to Cos-7 cells, which displayed adhesion-dependent Shc phosphorylation. Therefore, we expressed migration incompetent forms of Shc (Shc 3YF and Shc S154P) in FG-M cells to determine if Shc was required for the migration of these cells. As shown in Fig. 6, haptotaxis in FG-M cells was highly Shc-dependent, since expression of either Shc 3YF or Shc S154P dramatically inhibited haptotaxis towards vitronectin (by 76 and 83%, respectively). These results suggest that Shc is required for the spontaneous, haptotactic phenotype of these cells.
|
|
|
| Discussion |
|---|
|
|
|---|
Shc's signaling capacity is regulated by tyrosine phosphorylation. After activation of growth factor receptors and cytosolic tyrosine kinases, Shc becomes phosphorylated (McGlade et al. 1992; Pelicci et al. 1992) on residues 239/240 and 317 within the CH domain and binds Grb2 (Rozakis-Adcock et al. 1992; Salcini et al. 1994; Gotoh et al. 1996; van der Geer et al. 1996), ultimately resulting in the activation of Ras and ERK. However, the biological role of these residues in integrin signaling remains unclear. Recent reports have demonstrated a requirement for Shc Y317 for integrin-mediated ERK activity (Wary et al. 1996), while another report suggested that integrins can stimulate the ERK pathway independently of Y317 (Schlaepfer et al. 1998). In the current report, mutation of either of these sites alone resulted in a loss of Shc's ability to stimulate migration, suggesting that integrins can utilize both of these sites. Tyrosines 239/240 and 317 were crucial for EGF-stimulated mitogenesis in Cos-7 cells, in agreement with findings of others that these sites couple to distinct effectors in mitogenic signaling (Gotoh et al. 1996, Gotoh et al. 1997). In summary, Shc tyrosine phosphorylation does not distinguish between proliferative and cell migratory signaling pathways.
The observation that cytoskeletally associated kinases phosphorylate Shc (McGlade et al. 1992; Schlaepfer et al. 1998; Wary et al. 1998) suggests that recruitment of Shc to the actin-associated cytoskeleton is an important step in integrin signaling. Recent studies defined a role for the SH3 domain of the Src family member Fyn in this process (Wary et al. 1998). Presumably, the Fyn SH3 domain interacts with proline-rich regions in the CH domain of Shc. The PTB domain may also contribute to Shc recruitment. The amino-terminal domain of Shc was reported to mediate the association of this adaptor protein to an actin-rich cellular fraction (Thomas et al. 1995). In agreement with this report, we find that mutation of the PTB domain abolishes integrin-stimulated Shc tyrosine phosphorylation; the SH2 domain is dispensable for this process. The PTB can bind phospholipids (Zhou et al. 1995) which enhances Shc phosphorylation by cSrc (Sato et al. 1997). Taken together, these observations suggest a model in which the PTB domain localizes Shc to the membrane where it becomes phosphorylated by cytoskeletally associated tyrosine kinases, such as Src, Fyn and/or FAK after integrin ligation, which ultimately results in cell migration.
While Shc-dependent cell migration and proliferation depend upon tyrosine phosphorylation, these processes can be distinguished by their differential requirement for Shc's phosphotyrosine binding domains. The SH2 domain is selectively required for proliferation, as mutation of this domain dramatically inhibited EGF-stimulated DNA synthesis but had no effect on motility, or integrin-induced Shc phosphorylation. The PTB domain, in contrast, mediated tyrosine phosphorylation of Shc in response to integrin ligation and haptotactic cell migration. These findings may be biologically relevant for a number of processes. For example, Shc may play an important role during neural crest cell migration, when cells migrate along a haptotactic gradient without proliferating (Henderson and Copp 1997) or during wound healing when fibroblasts migrate in a fibrin-rich ECM (Martin 1997). However, when cells reach areas of high growth factor concentration, Shc may facilitate the cell proliferation response. Activation of the EGF receptor promotes the redistribution of Shc from a perinuclear to a plasma membrane localization (Lotti et al. 1996). EGF-R phosphorylation is required for this effect, presumably because receptor activation creates consensus binding sites for Shc's phosphotyrosine binding domains (Lotti et al. 1996). Thus, when growth factors are present, Shc may be recruited from areas where it transduces haptotactic signals, such as integrin containing focal contacts, to regions of the membrane containing growth factor receptors where it participates in mitogenic signaling.
In summary, proliferation and motility are controlled by adhesion proteins and growth factors associated with the ECM (Martin 1997). Integrin and growth factor receptor signals signal through the adaptor protein Shc to regulate these responses (Bonfini et al. 1996; Wary et al. 1996, Wary et al. 1998). We find that migratory and proliferative signals also bifurcate at the level of Shc. This divergence is characterized by differential requirements of the Shc PTB domain and the Shc SH2 domain.
Note added in proof. While this manuscript was being reviewed, Shc was reported to decreased focal adhesion organization and to increase cell migration in Gu, J., M. Tamura, R. Pankov, E.H.J. Danen, T. Takino, K. Matsumoto, and K.M. Yamada. 1999. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J. Cell Biol. 146:389–404.
| Acknowledgments |
|---|
This work was supported by National Institutes of Health grants CA50286, CA45726, HL54444, and P01CA78045 to D.A. Cheresh. L.R. Collins was supported by National Cancer Institute minority supplement CA45726-12S1. This is manuscript number 12586-IMM from The Scripps Research Institute.
Submitted: 15 July 1999
Revised: 11 October 1999
Accepted: 15 November 1999
Abbreviations used in this paper: ANOVA, analysis of variance; BrdU, bromodeoxyuridine; CH, collagen homology; ECM, extracellular matrix; ERK, extracellular signal-related kinase; FAK, focal adhesion kinase; SH2, Src homology 2; PTB, phosphotyrosine binding.
| References |
|---|
|
|
|---|
Anand-Apte B., Zetter B.R., Viswanathan A., Qiu R.G., Chen J., Ruggieri R. & Symons M.. Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways, J. Biol. Chem., 272, 1997, 30688–30692.
Blaikie P., Immanuel D., Wu J., Li N., Yajnik V. & Margolis B.. A region in Shc distinct from the SH2 domain can bind tyrosine-phosphorylated growth factor receptors, J. Biol. Chem., 269, 1994, 32031–32034.
Bonfini L., Migliaccio E., Pelicci G., Lanfrancone L. & Pelicci P.G.. Not all Shc's roads lead to Ras, Trends Biochem. Sci., 21, 1996, 257–261.[Medline]
Cowley S., Paterson H., Kemp P. & Marshall C.J.. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells, Cell, 77, 1994, 841–852.[Medline]
Gotoh N., Muroya K., Hattori S., Nakamura S., Chida K. & Shibuya M.. The SH2 domain of Shc suppresses EGF-induced mitogenesis in a dominant negative manner, Oncogene, 11, 1995, 2525–2533.[Medline]
Gotoh N., Tojo A. & Shibuya M.. A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL-3, EMBO (Eur. Mol. Biol. Organ.) J., 15, 1996, 6197–6204.[Medline]
Gotoh N., Toyoda M. & Shibuya M.. Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation, Mol. Cell. Biol., 17, 1997, 1824–1831.[Abstract]
Henderson D.J. & Copp A.J.. Role of the extracellular matrix in neural crest cell migration, J. Anat., 191, 1997, 507–515.[Medline]
Huttenlocher A., Sandborg R.R. & Horwitz A.F.. Adhesion in cell migration, Curr. Opin. Cell Biol., 7, 1995, 697–706.[Medline]
Klemke R.L., Cai S., Giannini A.L., Gallagher P.J., de Lanerolle P. & Cheresh D.A.. Regulation of cell motility by mitogen-activated protein kinase, J. Cell Biol., 137, 1997, 481–492.
Klemke R.L., Leng J., Molander R., Brooks P.C., Vuori K. & Cheresh D.A.. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration, J. Cell Biol., 140, 1998, 961–972.
Klemke R.L., Yebra M., Bayna E.M. & Cheresh D.A.. Receptor tyrosine kinase signaling required for integrin
vβ5-directed cell motility but not adhesion on vitronectin, J. Cell Biol., 127, 1994, 859–866.
Lauffenburger D.A. & Horwitz A.F.. Cell migrationa physically integrated molecular process, Cell, 84, 1996, 359–369.[Medline]
Lotti L.V., Lanfrancone L., Migliaccio E., Zompetta C., Pelicci G., Salcini A.E., Falini B., Pelicci P.G. & Torrisi M.R.. Sch proteins are localized on endoplasmic reticulum membranes and are redistributed after tyrosine kinase receptor activation, Mol. Cell. Biol., 16, 1996, 1946–1954.[Abstract]
Mainiero F., Pepe A., Wary K.K., Spinardi L., Mohammadi M., Schlessinger J. & Giancotti F.G.. Signal transduction by the alpha 6 beta 4 integrindistinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes, EMBO (Eur. Mol. Biol. Organ.) J., 14, 1995, 4470–4481.[Medline]
Martin P.. Wound healing—aiming for perfect skin regeneration, Science, 276, 1997, 75–81.
Mayer B.J., Jackson P.K., Van Etten R.A. & Baltimore D.. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo, Mol. Cell. Biol., 12, 1992, 609–618.
McGlade J., Cheng A., Pelicci G., Pelicci P.G. & Pawson T.. Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases, Proc. Natl. Acad. Sci. USA., 89, 1992, 8869–8873.
Nolan M.K., Jankowska L., Prisco M., Xu S., Guvakova M.A. & Surmacz E.. Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells, Intl. J. Cancer., 72, 1997, 828–834.[Medline]
Olson M.F., Ashworth A. & Hall A.. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1, Science, 269, 1995, 1270–1272.
Pages G., Lenormand P., L'Allemain G., Chambard J.C., Meloche S. & Pouyssegur J.. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation, Proc. Natl. Acad. Sci. USA., 90, 1993, 8319–8323.
Pelicci G., Giordano S., Zhen Z., Salcini A.E., Lanfrancone L., Bardelli A., Panayotou G., Waterfield M.D., Ponzetto C. & Pelicci P.G.. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein, Oncogene, 10, 1995, 1631–1638.[Medline]
Pelicci G., Lanfrancone L., Grignani F., McGlade J., Cavallo F., Forni G., Nicoletti I., Pawson T. & Pelicci P.G.. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction, Cell, 70, 1992, 93–104.[Medline]
Perris R.. The extracellular matrix in neural crest-cell migration, Trends Neurosci, 20, 1997, 23–31.[Medline]
Ricketts W.A., Brown J.H. & Olefsky J.M.. Pertussis toxin sensitive and insensitive thrombin signaling to shc and mitogenesis are mediated through distinct pathways, Mol. Endocrinol., In press, 1999.
Ricketts W.A., Rose D.W., Shoelson S. & Olefsky J.M.. Functional roles of the Shc phosphotyrosine binding and Src homology 2 domains in insulin and epidermal growth factor signaling, J. Biol. Chem., 271, 1996, 26165–26169.
Risau W.. Mechanisms of angiogenesis, Nature, 386, 1997, 671–674.[Medline]
Rozakis-Adcock M., McGlade J., Mbamalu G., Pelicci G., Daly R., Li W., Batzer A., Thomas S., Brugge J. & Pelicci P.G.. Association of the Shc and Grb2/Sem5 SH2–containing proteins is implicated in activation of the Ras pathway by tyrosine kinases, Nature, 360, 1992, 689–692.[Medline]
Salcini A.E., McGlade J., Pelicci G., Nicoletti I., Pawson T. & Pelicci P.G.. Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins, Oncogene, 9, 1994, 2827–2836.[Medline]
Sato K., Gotoh N., Otsuki T., Kakumoto M., Aoto M., Tokmakov A.A., Shibuya M. & Fukami Y.. Tyrosine residues 239 and 240 of Shc are phosphatidylinositol 4,5-bisphosphate-dependent phosphorylation sites by c-Src, Biochem. Biophys. Res. Commun., 240, 1997, 399–404.[Medline]
Schlaepfer D.D., Jones K.C. & Hunter T.. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinasesummation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events, Mol. Cell. Biol., 18, 1998, 2571–2585.
Thomas D. & Bradshaw R.A.. Differential utilization of ShcA tyrosine residues and functional domains in the transduction of epidermal growth factor-induced mitogen-activated protein kinase activation in 293T cells and nerve growth factor-induced neurite outgrowth in PC12 cells. Identification of a new Grb2.Sos1 binding site, J. Biol. Chem., 272, 1997, 22293–22299.
Thomas D., Patterson S.D. & Bradshaw R.A.. Src homologous and collagen (Shc) protein binds to F-actin and translocates to the cytoskeleton upon nerve growth factor stimulation in PC12 cells, J. Biol. Chem., 270, 1995, 28924–28931.
van der Geer P., Wiley S., Gish G.D. & Pawson T.. The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein-protein interactions, Curr. Biol., 6, 1996, 1435–1444.[Medline]
Wary K.K., Mainiero F., Isakoff S.J., Marcantonio E.E. & Giancotti F.G.. The adaptor protein Shc couples a class of integrins to the control of cell cycle progression, Cell, 87, 1996, 733–743.[Medline]
Wary K.K., Mariotti A., Zurzolo C. & Giancotti F.G.. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth, Cell, 94, 1998, 625–634.[Medline]
Zhou M.M., Ravichandran K.S., Olejniczak E.F., Petros A.M., Meadows R.P., Sattler M., Harlan J.E., Wade W.S., Burakoff S.J. & Fesik S.W.. Structure and ligand recognition of the phosphotyrosine binding domain of Shc, Nature, 378, 1995, 584–592.[Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|